Mirna Therapeutics (Austin, TX), a pre-clinical biologics company developing micro-RNA directed oncology therapies, closed a $34.5M Series C financing. Participants include Sofinnova Ventures, New Enterprise Associates, Pfizer Ventures, Osage University Partners and Correlation Ventures.


Collective IP | The Most Comprehensive and Accurate View of Global Innovation and Organization of the International Technology Transfer Office Ecosystem

Request Account Access HERE